HC Wainwright & Co. Reiterates Nuvectis Pharma (NVCT) Buy Recommendation
Fintel reports that on September 15, 2023, HC Wainwright & Co. reiterated coverage of Nuvectis Pharma (NASDAQ:NVCT) with a Buy recommendation.
Symbol | Last Price | Change | % Change |
---|---|---|---|